1-18 of 18
Liza Lindenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Allison Graeter, Christopher Melani, Max J Gordon, Jagan R. Muppidi, Sam Y. Ng, Sumaya Berg, Sarah Evans, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Bonita Bryant, Yandan Yang, Theresa Davies-Hill, Liza Lindenberg, Mark Ahlman, Esther Mena, Ethan Bergvall, Nick Micheletti, Laura M Yee, Allison P. Jacob, Monica Gallucci, Heidi Simmons, Alexander Bagaev, Mark Meerson, Ekaterina Postovalova, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2024) 144 (Supplement 1): 2958.
https://doi.org/10.1182/blood-2024-201711
Published: 2024
Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Roshani Patel, Amrit Bhaskarla, Max J Gordon, Michael Emanuel, Dana I. Delgado Colon, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nick Micheletti, Laura M Yee, Nisha Patel, Irina Maric, Raul C. Braylan, Katherine R. Calvo, Louis M. Staudt, Ryan M. Young, Mark Roschewski, Dickran Kazandjian, Elizabeth Hill
Journal: Blood
Blood (2024) 144 (Supplement 1): 7059.
https://doi.org/10.1182/blood-2024-201563
Published: 2024
Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, Christopher Melani, Jagan R. Muppidi, Stefania Pittaluga, James D Phelan, Colleen Ramsower, Lisa M. Rimsza, Ryan S Robertorye, George Wright, Mark Meerson, Ekaterina Postovalova, Alexander Bagaev, Nathan Fowler, Liza Lindenberg, Esther Mena, Ethan Bergvall, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Sumaya Berg, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2023-185038
Published: 2023
Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 192.
https://doi.org/10.1182/blood-2023-180007
Published: 2023
Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Elizabeth Hill, Joseph L. Roswarski, Amrit Bhaskarla, Alexander Dew, Candis Morrison, Michael Emanuel, Ani Petrosyan, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nisha Patel, Irina Maric, Alina Dulau-Florea, Katherine Calvo, Raul C. Braylan, Maryalice Stetler-Stevenson, Seth M. Steinberg, William Figg, Ryan M. Young, Ola Landgren, Mark Roschewski, Dickran Kazandjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 337.
https://doi.org/10.1182/blood-2023-181811
Published: 2023
Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136182
Published: 2020
Journal Articles

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Elizabeth Hill, MD, Baris Turkbey, MD, Evrim Turkbey, MD, Candis Morrison, CNP, PhD, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-136185
Published: 2020
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Dickran Kazandjian, MD, Neha Korde, MD, Sham Mailankody, MBBS, Yong Zhang, PhD, Jennifer Hsu, RN, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Sneha Divakarla, MHA, Mary L. Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Pallavi Galera, Alina Dulau-Florea, MD, Dalia Salem, MD, Esther Gonzalez, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Katherine R. Calvo, MD PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Wyndham H. Wilson, MD PhD, Peter Choyke, MD, Maryalice Stetler-Stevenson, MD PhD, Seth M. Steinberg, PhD, William Figg, PharmD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1957.
https://doi.org/10.1182/blood-2018-99-111712
Published: 2018
Journal Articles

Longitudinal 18 f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)

Neha S Korde, MD, Dickran Kazandjian, MD, Mark Roschewski, MD, Sham Mailankody, MD, Malin Hultcrantz, MD, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Peter Choyke, MD, Hani Hassoun, MD, Alexander M. Lesokhin, MD, Nikoletta Lendvai, MDPhD, Eric L. Smith, MD PhD, Ola Landgren, MDPhD, Karen A. Kurdziel, MD, Maria Liza Lindenberg, MD
Journal: Blood
Blood (2016) 128 (22): 3274.
https://doi.org/10.1182/blood.V128.22.3274.3274
Published: 2016
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study

Ola Landgren, MD PhD, Mark Roschewski, MD, Sham Mailankody, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Adriana Zingone, MD PhD, Rene Costello, Debra Burton, Yong Zhang, MD PhD, Peter Wu, George Carter, PA, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Ashley Carpenter, RN, Verena Gounden, MD, Candice Morrison, NP, Irina Maric, MD, Katherine R. Calvo, MD, PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C Arthur, MD, Liza Lindenberg, MD, Kurdziel Karen, MD, Peter Choyke, MD, Seth M. Steinberg, PhD, William D Figg, PharmD, Neha Korde, MD
Journal: Blood
Blood (2014) 124 (21): 4746.
https://doi.org/10.1182/blood.V124.21.4746.4746
Published: 2014
Journal Articles

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Kirsten M Williams, MD, Jennifer L. Holter Chakrabarty, MD, Liza Lindenberg, MD, Steve Adler, Juan Gea-Banacloche, MD, Bazetta Blacklock-Schuver, RN, Frances T. Hakim, PhD, Dennis D. Hickstein, MD, James N Kochenderfer, MD, Jennifer Wilder, Tracey Chinn, RN, Karen Kurdziel, MD, Seth M. Steinberg, PhD, Hanh Khuu, Frank I Lin, Daniel H. Fowler, MD, David Halverson, MD, Daniele N. Avila, CRNP, George Selby, MD, Tiffani N. Taylor, PA, Jennifer Mann, Jennifer Hsu, RN, Robert B. Epstein, MD, Stacy L Anderson, Nguyen Chuong, Joseph Havlicek, Shibo Li, MD, Tom Pham, Teresa Kraus, Sara K. Vesely, PhD MPH, Steven Z. Pavletic, MD, Catherine M. Bollard, MBChB, MD, Peter Choyke, MD, Ronald E Gress, MD
Journal: Blood
Blood (2014) 124 (21): 1147.
https://doi.org/10.1182/blood.V124.21.1147.1147
Published: 2014
Journal Articles

Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients

Ola Landgren, MD, PhD, Sham Mailankody, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Adriana Zingone, MD, PhD, Rene Costello, Debra Burton, Yong Zhang, PhD, Peter Wu, George Carter, PA, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Liza Lindenberg, MD, Karen Kurdziel, MD, Peter Choyke, MD, Seth M. Steinberg, PhD, Mark Roschewski, MD, Neha Korde, MD
Journal: Blood
Blood (2013) 122 (21): 1939.
https://doi.org/10.1182/blood.V122.21.1939.1939
Published: 2013
Journal Articles

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Neha Korde, MD, Adriana Zingone, MD, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Sham Mailankody, MD, Rene Costello, Yong Zhang, PhD, Debra Burton, George Carter, PA, Peter Wu, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Mark Roschewski, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Liza Lindenberg, MD, Karen Kurdziel, MD, Pete Choyke, MD, Seth M. Steinberg, PhD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 538.
https://doi.org/10.1182/blood.V122.21.538.538
Published: 2013
Journal Articles

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Neha Korde, MD, Adriana Zingone, MD, PhD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Rene Costello, Diamond Zuchlinski, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, MD, Constance Yuan, MD, PhD, Prashant Ramesh Tembhare, MD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Mark Raffeld, MD, Liqiang Xi, MD, Peter Choyke, MD, Karen Kurdziel, MD, Liza Lindenberg, MD, Seth M. Steinberg, PhD, Mark Roschewski, MD, Ola Landgren, M.D., Ph.D.
Journal: Blood
Blood (2012) 120 (21): 732.
https://doi.org/10.1182/blood.V120.21.732.732
Published: 2012
Journal Articles

Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study

Esther Tan, MD, Liza Lindenberg, MD, Neha Korde, MD, Alexandra Berg, Esther Mena, MD, Baris Turkbey, MD, Omer Aras, MD, Seth M. Steinberg, PhD, Brendan Weiss, MD, Alex Minter, MD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Peter Choyke, MD, Karen Kurdziel, MD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2888.
https://doi.org/10.1182/blood.V118.21.2888.2888
Published: 2011